RJ Hamster
All Eyes Tomorrow: Why We’ll Be Locked In On…
 *Disseminated on Behalf of Medicus Pharma Ltd.Market Crux Announces (NASDAQ: MDCX) Is Back On Our Radar! Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email.See Why (MDCX) Will Be Topping Our Watchlist Tomorrow Morning —Monday, November 17, 2025 (MDCX) Comes Backed By Several Potential Catalysts, Keep Reading To See What We Can Tell You Right Now…Get (MDCX) On Your Screen Before Monday’s Bell Rings… November 16, 2025 All Eyes Tomorrow | Why We’ll Be Locked In On (MDCX) First ThingDear Reader,Every once in a while, a profile shifts gears overnight—quiet momentum gives way to something sharper, something you can’t afford to overlook.That’s exactly what’s happening with Medicus Pharma Ltd. (NASDAQ: MDCX).A cluster of fresh catalysts hit just as we head into Monday morning, November 17, 2025—and it’s put this name right back on our radar in a big way.Keep in mind, (MDCX) has an ultra-small float, with fewer than 8M shares listed as available to the public according to MarketWatch. When floats are this small, there’s often potential for sharp moves if demand begins to shift.The chart now shows (MDCX) was recently trending near several key moving averages, showcasing potential technical strength.Recently, (MDCX) made an approximate 70% move in just three weeks—from $1.79 on September 4 to $3.05 on September 23—and could now be drawing sharper attention to what might come next.Insider ownership remains above 35%, a level that often reflects management confidence in a company’s long-term direction.Together, these signals point toward potential for continued momentum.Analyst Targets Suggests Over 1,100% Upside Potential From Recent Range…  Multiple market outlets, including Benzinga, MarketWatch, and TipRanks, have reported that D. Boral Capital analyst Jason Kolbert recently set a $27 target on (MDCX), suggesting over 1,100% upside potential from its recent $2.20 range.That’s not the only target now in play.Brookline Capital’s Kumaraguru Raja recently raised his target from $12 to $20, while Maxim Group’s Jason McCarthy reiterated a $20 target in a report published a few days ago—reflecting continued confidence and over 800% upside potential from current levels.Following its recent acquisition of Antev Limited, (MDCX) has expanded into two late-stage therapeutic programs addressing major clinical needs.With analyst coverage, regulatory progress, and technical momentum all converging, (MDCX) stands out as one of the biotech names to watch heading into this morning’s session.Just Hit After the Close: A Fresh Q3 Update From (MDCX) Most People Haven’t Seen Yet…(MDCX) quietly released a new Q3 update late Friday—well after the bell—meaning most people haven’t seen it yet. The filing confirmed 75% enrollment in its U.S. Phase 2 SkinJect trial, supportive FDA Type C feedback for the 505(b)(2) pathway, and first-patient dosing in its second Phase 2 study. The SkinJect program is also expanding with newly approved sites in the U.K.The update also highlighted its MoU with HelixNano, continued integration of Antev, and FDA-cleared Phase 2b progress for Teverelix.Financially, (MDCX) strengthened its balance sheet with $10.4M in new capital, raising ca-sh to $8.7M. Management reiterated high confidence in the growing SkinJect footprint and the potential of Teverelix across two major treatment areas.FDA Feedback Strengthens (MDCX)’s Path Toward Next-Gen Skin Cancer Treatment  Medicus Pharma Ltd. (NASDAQ: MDCX) has announced positive feedback from a Type C meeting with the U.S. FDA regarding its SkinJect program — a dissolvable microneedle patch designed to non-invasively treat basal cell carcinoma (BCC).The FDA agreed that the company may pursue the 505(b)(2) regulatory pathway, a streamlined route that could reduce both cost and development time by leveraging existing doxorubicin safety data.The agency also provided constructive guidance on study design, endpoints, and formulation refinements, including recommendations for an adhesive layer and applicator system to improve precision and consistency.(MDCX) is currently advancing two Phase 2 studies for its SkinJect program.In the United States, the SKNJCT-003 trial has already enrolled more than 75% of its planned 90 participants and continues to show encouraging progress following a positively trending interim analysis earlier this year.At the same time, a second Phase 2 study (SKNJCT-004) is underway across six clinical sites in the United Arab Emirates, including Cleveland Clinic Abu Dhabi and Sheikh Shakbout Medical City.The company expects to complete patient recruitment for SKNJCT-003 before the end of Q4 2025 and to request an End-of-Phase 2 meeting with the FDA in Q1 2026.Medicus estimates that the market potential for non-invasive BCC treatments could approach $2B annually.Executive Chairman and CEO Dr. Raza Bokhari stated that the FDA’s feedback “marks an important step toward establishing SkinJect as a potential first-in-market, non-invasive therapy for BCC,” adding that confidence continues to grow as development progresses.(MDCX) Expands Compassionate Use Access With New CollaborationMedicus Pharma Ltd. (NASDAQ: MDCX) announced a collaboration with the Gorlin Syndrome Alliance (GSA)to pursue a compassionate use pathway for its investigational SkinJect™ microneedle patch in patients with Gorlin Syndrome, a rare genetic condition affecting roughly 1 in 31,000 people worldwide.The partnership will jointly advance an Expanded Access IND Program with the FDA, allowing eligible patients with multiple or inoperable basal cell carcinomas to access SkinJect™ under physician supervision.The initiative also aims to collect real-world safety data while incorporating patient insights into ongoing development.Executive Chairman and CEO Dr. Raza Bokhari noted that the collaboration reflects (MDCX)’s mission to bring targeted innovation to conditions with significant unmet medical needs.First Patient Treated in UAE Marks Key Milestone in Global Phase 2 Expansion  Just this week, Medicus Pharma Ltd. (NASDAQ: MDCX) announced that its first patient has been treated in the UAE SKNJCT-004 Phase 2 study for its SkinJect program—designed to non-invasively treat basal cell carcinoma (BCC).Cleveland Clinic Abu Dhabi is serving as the principal investigator, with additional recruitment planned across five major regional hospitals including Sheikh Shakbout Medical City and American Hospital Dubai.The study will enroll 36 participants across six UAE sites, coordinated by Insights Research Organization and Solutions (IROS), a member of the M42 healthcare portfolio.According to Dr. Raza Bokhari, Executive Chairman and CEO, this milestone “marks an important step in expanding Medicus’s clinical footprint beyond the U.S.,” underscoring the company’s push to position SkinJect as a potential first-in-market non-invasive treatment for BCC—a global condition representing more than $2B in annual market potential.(MDCX) Bolsters Clinical Portfolio With Teverelix—A Dual-Use Phase 2b CandidateMedicus Pharma (NASDAQ: MDCX) has completed its acquisition of Antev Limited, gaining control of Teverelix trifluoroacetate, a next-generation GnRH antagonist in late-stage development for both acute urinary retention (AURr) and high cardiovascular-risk prostate cancer.The move broadens (MDCX)’s clinical scope into two therapeutic areas with a combined $6B market potential. Teverelix is designed for dual use: in AURr, a condition with high recurrence rates, it aims to become the first product to prevent relapse, supported by an FDA-cleared Phase 2b study of 390 patients.In prostate cancer patients with elevated cardiovascular risk, it is being evaluated in another FDA-cleared Phase 2b trial as a potentially safer alternative to conventional therapies.The acquisition also adds leadership depth, with veteran pharma executive Patrick J. Mahaffy joining the board.Together, the expanded pipeline and strengthened leadership put (MDCX) in position to reshape care across two areas of pressing medical need.Turning Point Ahead as Momentum Builds for (MDCX) With late-stage programs advancing, growing clinical progress, and key regulatory steps approaching, (MDCX) is entering a pivotal phase.Momentum potential across its strategy and leadership has placed it firmly on our radar—and seven factors now stand out heading into this morning’s session.7 Factors Putting (MDCX) at the Top of Our Watchlist Tomorrow Morning—Monday, November 17, 2025 1. Analyst Coverage: three firms—D. Boral Capital, Brookline Capital, and Maxim Group—have each reaffirmed bullish views on (MDCX), with targets reaching as high as $27, reflecting roughly 1,100% upside potential from recent levels.2. Small Float: with fewer than 8M shares available to the public, (MDCX)’s small float could see the potential for big moves if demand begins to shift.3. Technical Strength: the chart for (MDCX) shows it trending near several key moving averages.4. Recent Momentum: after an approximate 70% move in just three weeks last month, (MDCX) continues to attract focus from those tracking continuation patterns across the biotech sector.5. Insider Confidence: leadership holds over 35% (MDCX)’s shares, signaling strong alignment between internal vision and long-term goals.6. Global Expansion: with its first patient treated in the UAE and additional sites now active, (MDCX)’s SkinJect program continues to demonstrate tangible progress on an international scale.7. Latest Update: A fresh late-Friday Q3 release from (MDCX) confirmed new clinical progress, expanded international approvals, and a strengthened balance sheet that most people haven’t reacted to yet.All seven factors point to one conclusion—(MDCX) is entering a decisive stretch.With multiple potential catalysts aligning across its pipeline, this morning stands out as a moment to keep (MDCX) at the top of your radar.Get (MDCX) On Your Screen Before Monday’s Bell Rings…  With potential momentum building on multiple fronts, (MDCX) is standing out for all the right reasons.The company’s low float of fewer than 8M shares, strong insider ownership above 35%, and technical strength across multiple moving averages together form a setup that’s difficult to overlook.Add in its expanding global Phase 2 work for SkinJect, the recent Antev acquisition, fresh analyst targets reaching as high as $27, which suggests 1,100% upside potential from recent levels, and a late-Friday Q3 updateconfirming new clinical progress, expanded approvals, and a strengthened balance sheet that most people haven’t reacted to yet—it’s clear why attention continues to build around this name.Tomorrow morning’s focus is already set—and (MDCX) is on it.Have a quick look tonight before you shut down for the evening, and stay tuned for my morning briefing.Have a good night.Sincerely,Gary Silver Managing Editor, Market Crux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, MC is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 11/16/2025 and ending on 11/17/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid twenty nine thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.Neither Headline Media LLC, TD Media LLC and their member own shares of (MDCX:US).Please see important disclosure information here: https://marketcrux.com/disclosure/mdcx-ZHXUT/#details |
| Headline Media | 7901 4th Street N, Suite 300, St. Petersburg, FL 33702UnsubscribeUpdate Profile | Constant Contact Data NoticeSent by gary@marketcrux.net |
